TY - JOUR T1 - Rare Non-coding Variation Identified by Large Scale Whole Genome Sequencing Reveals Unexplained Heritability of Type 2 Diabetes JF - medRxiv DO - 10.1101/2020.11.13.20221812 SP - 2020.11.13.20221812 AU - Jennifer Wessel AU - Timothy D Majarian AU - Heather M Highland AU - Sridharan Raghavan AU - Mindy D Szeto AU - Natalie R Hasbani AU - Paul S de Vries AU - Jennifer A Brody AU - Chloé Sarnowski AU - Daniel DiCorpo AU - Xianyong Yin AU - Bertha Hidalgo AU - Xiuqing Guo AU - James Perry AU - Jeffrey R O’Connell AU - Samantha Lent AU - May E Montasser AU - Brian E Cade AU - Deepti Jain AU - Heming Wang AU - Peitao Wu AU - Silvia Bonàs-Guarch AU - Ricardo D’Oliveira Albanus AU - Aaron Leong AU - Irene Miguel-Escalada AU - Arushi Varshney AU - NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium, TOPMed Anthropometry, DIAMANTE AU - Gregory L Kinney AU - Lisa R Yanek AU - Leslie Lange AU - Marcio Almeida AU - Juan M Peralta AU - Stella Aslibekyan AU - Abigail S Baldridge AU - Alain G Bertoni AU - Lawrence F Bielak AU - Donald W Bowden AU - Chung-Shiuan Chen AU - Yii-Der Ida Chen AU - Seung Hoan Choi AU - Won Jung Choi AU - Dawood Darbar AU - James S Floyd AU - Barry I Freedman AU - Mark O Goodarzi AU - Ryan Irvin AU - Rita R Kalyani AU - Tanika Kelly AU - Seonwook Lee AU - Ching-Ti Liu AU - Douglas Loesch AU - JoAnn E Manson AU - Rami Nassir AU - Nicholette D Palmer AU - James S Pankow AU - Laura J Rasmussen-Torvik AU - Alexander P Reiner AU - Elizabeth Selvin AU - Aladdin H Shadyab AU - Jennifer A Smith AU - Daniel E Weeks AU - Lu-Chen Weng AU - Huichun Xu AU - Jie Yao AU - Zachary Yoneda AU - Wei Zhao AU - Jorge Ferrer AU - Anubha Mahajan AU - Mark I McCarthy AU - Stephen Parker AU - Alvaro Alonso AU - Donna K Arnett AU - John Blangero AU - Eric Boerwinkle AU - Michael H Cho AU - Adolfo Correa AU - L. Adrienne Cupples AU - Joanne E Curran AU - Ravindranath Duggirala AU - Patrick T Ellinor AU - Jiang He AU - Susan R Heckbert AU - Sharon LR Kardia AU - Ryan W Kim AU - Charles Kooperberg AU - Simin Liu AU - Steven A Lubitz AU - Rasika A Mathias AU - Stephen McGarvey AU - Braxton D Mitchell AU - Alanna C Morrison AU - Patricia A Peyser AU - Bruce M Psaty AU - Susan Redline AU - Dan Roden AU - M. Benjamin Shoemaker AU - Nicholas L Smith AU - Kent D Taylor AU - Ramachandran S Vasan AU - Karine A Viaud-Martinez AU - Jose C Florez AU - James G Wilson AU - Robert Sladek AU - Josée Dupuis AU - Stephen S Rich AU - Jerome I Rotter AU - James B Meigs AU - Alisa K Manning Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/11/16/2020.11.13.20221812.abstract N2 - Type 2 diabetes is increasing in all ancestry groups1. Part of its genetic basis may reside among the rare (minor allele frequency <0.1%) variants that make up the vast majority of human genetic variation2. We analyzed high-coverage (mean depth 38.2x) whole genome sequencing from 9,639 individuals with T2D and 34,994 controls in the NHLBI’s Trans-Omics for Precision Medicine (TOPMed) program2 to show that rare, non-coding variants that are poorly captured by genotyping arrays or imputation panels contribute h2=53% (P=4.2×10−5) to the genetic component of risk in the largest (European) ancestry subset. We coupled sequence variation with islet epigenomic signatures3 to annotate and group rare variants with respect to gene expression4, chromatin state5 and three-dimensional chromatin architecture6, and show that pancreatic islet regulatory elements contribute to T2D genetic risk (h2=8%, P=2.4×10−3). We used islet annotation to create a non-coding framework for rare variant aggregation testing. This approach identified five loci containing rare alleles in islet regulatory elements that suggest novel biological mechanisms readily linked to hypotheses about variant-to-function. Large scale whole genome sequence analysis reveals the substantial contribution of rare, non-coding variation to the genetic architecture of T2D and highlights the value of tissue-specific regulatory annotation for variant-to-function discovery.Competing Interest StatementAnubha MahajanAs of January 2020, A.M. is an employee of Genentech, and a holder of Roche stock. Patrick T. EllinorDr. Ellinor is supported by a grant from Bayer AG to the Broad Institute focused on the genetics and therapeutics of cardiovascular disease. Dr. Ellinor has consulted for Bayer AG, Novartis and Quest Diagnostics. Jose FlorezDr. Florez has received a consulting honorarium from Goldfinch Bio. and speaker fees from Novo Nordisk James S. FloydDr. Floyd has consulted for Shionogi Inc Barry I. FreedmanDr. Freedman is a consultant for RenalytixAI and AstraZeneca Pharmaceuticals Steven A. LubitzDr. Lubitz receives sponsored research support from Bristol Myers Squibb / Pfizer, Bayer HealthCare, and Boehringer Ingelheim, and has consulted for Abbott, Quest Diagnostics, Bristol Myers Squibb / Pfizer. Ed SilvermanGrant support from GSK and Bayer Michael H. ChoGrant support from GSK; consulting fees from Genentech Bruce M. PsatyPsaty serves on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson. Stella AslibekyanSA holds equity in 23andMe, Inc. Mark I McCarthyThe views expressed in this article are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. M.I.MM.McC. has served on advisory panels for Pfizer, NovoNordisk and Zoe Global, has received honoraria from Merck, Pfizer, Novo Nordisk and Eli Lilly, and research funding from Abbvie, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, NovoNordisk, Pfizer, Roche, Sanofi Aventis, Servier, and Takeda. As of June 2019, M.McC. is an employee of Genentech, and a holder of Roche stock.Funding StatementSee Supplementary Tables (SUPPL.TABLES.Funding.13NOV2020.xlsx) for funding statements from TOPMed, study, individual and resources. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All study participants provided informed consent, and each study's Institutional Review Board [or ethics review committee] provided approval. Details are provided in provided Supplementary Table (SUPP.TABLE.ParentStudy.Ethics.Statements.xlsx).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available on the Accelerating Medicines Partnership Type 2 Diabetes Knowledge Portal website. http://t2d.hugeamp.org/ ER -